Renaissance Technologies Portfolio holdings
Renaissance Technologies LLC, founded in 1982 by mathematician James Simons as Monemetrics and headquartered in East Setauket, New York, is a legendary quantitative hedge fund managing around $65 billion in assets as of late 2024, renowned for its pioneering use of mathematical models and algorithms in trading. Starting with currency trading and evolving into a secretive powerhouse under its flagship Medallion Fund—launched in 1988—the firm employs PhDs, physicists, and computer scientists to analyze vast datasets, executing high-frequency trades across equities, futures, and derivatives with returns averaging over 66% annually before fees from 1988 to 2018. Simons, who stepped down as chairman in 2021, built a culture of intellectual rigor, limiting Medallion to employees and insiders since 1993 while offering institutional funds like the Renaissance Institutional Equities Fund (RIEF) to outsiders. Now led by Peter Brown and Robert Mercer’s successors, Renaissance remains a benchmark for quant investing, blending academic precision with a low-profile, extraordinarily profitable legacy despite occasional regulatory scrutiny.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$856M |
| 2 |
Meta Platforms (Facebook)
META
|
+$647M |
| 3 |
NVIDIA
NVDA
|
+$615M |
| 4 |
Berkshire Hathaway Class A
BRK.A
|
+$304M |
| 5 |
Alphabet (Google) Class A
GOOGL
|
+$301M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Amazon
AMZN
|
+$1.03B |
| 2 |
UnitedHealth
UNH
|
+$686M |
| 3 |
Tesla
TSLA
|
+$387M |
| 4 |
Abbott
ABT
|
+$380M |
| 5 |
Chevron
CVX
|
+$328M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 20.26% |
| 2 | Healthcare | 16.96% |
| 3 | Consumer Discretionary | 12.82% |
| 4 | Consumer Staples | 9.14% |
| 5 | Industrials | 9.03% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2526
Invesco S&P 500 Top 50 ETF
XLG
$10.6B
| $909K | ﹤0.01% |
+26,000
| New | +$847K |
|
2527
Barnwell Industries
BRN
$14.8M
| $908K | ﹤0.01% |
356,222
-27,800
| -7% | -$75.1K |
|
2528
OptimizeRx
OPRX
$114M
| $907K | ﹤0.01% |
63,500
-120,900
| -66% | -$1.72M |
|
2529
Schwab US Large- Cap ETF
SCHX
$71.8B
| $906K | ﹤0.01% |
+51,900
| New | +$857K |
|
2530
First US Bancshares
FUSB
$91.1M
| $905K | ﹤0.01% |
105,821
-900
| -0.8% | -$6.77K |
|
2531
Equity Lifestyle Properties
ELS
$12.6B
| $904K | ﹤0.01% |
+13,519
| New | +$900K |
|
2532
Ultragenyx Pharmaceutical
RARE
$2.45B
| $904K | ﹤0.01% |
+19,600
| New | +$909K |
|
2533
Precision BioSciences
DTIL
$180M
| $903K | ﹤0.01% |
57,222
+6,344
| +12% | +$145K |
|
|
ITI
2534
DELISTED
Iteris, Inc.
ITI
| $902K | ﹤0.01% |
227,685
-19,175
| -8% | -$85.6K |
|
2535
Vanguard FTSE Pacific ETF
VPL
$8.08B
| $899K | ﹤0.01% |
12,900
-36,400
| -74% | -$2.51M |
|
2536
Minerva Neurosciences
NERV
$185M
| $898K | ﹤0.01% |
98,300
-12,500
| -11% | -$66K |
|
|
FOCS
2537
DELISTED
Focus Financial Partners Inc. Class A
FOCS
| $898K | ﹤0.01% |
17,100
-36,200
| -68% | -$1.89M |
|
2538
Vanguard Long-Term Corporate Bond ETF
VCLT
$8.81B
| $895K | ﹤0.01% |
+11,400
| New | +$891K |
|
|
CARM
2539
DELISTED
Carisma Therapeutics
CARM
| $892K | ﹤0.01% |
101,760
+33,465
| +49% | +$182K |
|
2540
SkyWater Technology
SKYT
$1.6B
| $892K | ﹤0.01% |
94,700
-9,567
| -9% | -$92K |
|
2541
Ponce Financial Group
PDLB
$488M
| $891K | ﹤0.01% |
102,494
-8,100
| -7% | -$63.2K |
|
2542
Spruce Power Holding Corp
SPRU
$35.8M
| $891K | ﹤0.01% |
137,225
+2,787
| +2% | +$17.4K |
|
2543
Direxion Daily 20+ Year Treasury Bear 3X ETF
TMV
$193M
| $891K | ﹤0.01% |
+30,800
| New | +$880K |
|
2544
Virco
VIRC
$95.2M
| $890K | ﹤0.01% |
213,364
+14,034
| +7% | +$55.7K |
|
|
XOMA
2545
DELISTED
Xoma
XOMA
| $890K | ﹤0.01% |
47,100
+35,499
| +306% | +$665K |
|
|
ZIMV
2546
DELISTED
ZimVie
ZIMV
| $885K | ﹤0.01% |
78,800
-19,311
| -20% | -$188K |
|
|
ASM
2547
Avino Silver & Gold Mines
ASM
$934M
| $884K | ﹤0.01% |
1,339,500
+436,400
| +48% | +$344K |
|
2548
Bakkt Inc
BKKT
$321M
| $884K | ﹤0.01% |
28,764
+7,356
| +34% | +$258K |
|
2549
Larimar Therapeutics
LRMR
$397M
| $881K | ﹤0.01% |
281,574
+98,832
| +54% | +$403K |
|
|
TRT
2550
Trio-Tech International
TRT
$101M
| $880K | ﹤0.01% |
365,726
-8,566
| -2% | -$19.8K |
|
Similar funds
Renaissance Technologies's Q2 2023 Portfolio in Review
As of Q2 2023, Renaissance Technologies held 4,468 positions worth $69.4B, down 7.9% from $75.4B the previous quarter. Its ten largest holdings account for 12% of the portfolio.
Renaissance Technologies withdrew a net $8.1B in Q2 2023, closing 599 positions and reducing 1,691 holdings. Its most notable exit was UnitedHealth, an estimated $686M position sold in full.
By sector, the portfolio is most concentrated in Technology at 20% of assets, up from 17% a quarter earlier, followed by Healthcare and Consumer Discretionary.
Against the trend, Renaissance Technologies opened a new position in Berkshire Hathaway Class A worth $316M.
- Renaissance Technologies's largest Q2 2023 buy was Berkshire Hathaway Class A: 611 shares worth $316M.
- Renaissance Technologies added most to Apple in Q2 2023, an estimated $856M increase.
- Renaissance Technologies's biggest Q2 2023 reduction was Amazon, cutting an estimated $1.03B.
- Renaissance Technologies fully exited UnitedHealth in Q2 2023, selling an estimated $686M.
- Renaissance Technologies's ten largest holdings make up 12% of its $69.4B portfolio in Q2 2023.
- Renaissance Technologies opened 542 new positions and closed 599 in Q2 2023.
- Renaissance Technologies's portfolio value fell 7.9% quarter-over-quarter to $69.4B.
Based on Renaissance Technologies's 13F filing for Q2 2023, filed 11 Aug 2023.